دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Diabetes: knowing your risk matters
doi : 10.1016/S2213-8587(23)00326-1
Volume 11, Issue 12, December 2023, Page 879
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY
doi : 10.1016/S2213-8587(23)00263-2
Volume 11, Issue 12, December 2023, Pages 880-881
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00291-7
Volume 11, Issue 12, December 2023, Pages 892-894
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00290-5
Volume 11, Issue 12, December 2023, Page 894
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00289-9
Volume 11, Issue 12, December 2023, Pages 894-895
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply
doi : 10.1016/S2213-8587(23)00292-9
Volume 11, Issue 12, December 2023, Pages 895-896
Metabolic non-communicable diseases in India: time to act
doi : 10.1016/S2213-8587(23)00297-8
Volume 11, Issue 12, December 2023, Pages 896-897
Metabolic non-communicable diseases in India: time to act
doi : 10.1016/S2213-8587(23)00298-X
Volume 11, Issue 12, December 2023, Pages 897-898
Metabolic non-communicable diseases in India: time to act – Authors' reply
doi : 10.1016/S2213-8587(23)00296-6
Volume 11, Issue 12, December 2023, Pages 898-899
Correction to Lancet Diabetes Endocrinol 2023; 11: 720–30
doi : 10.1016/S2213-8587(23)00319-4
Volume 11, Issue 12, December 2023, Page e14
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
doi : 10.1016/S2213-8587(23)00253-X
Volume 11, Issue 12, December 2023, Pages 905-914
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
doi : 10.1016/S2213-8587(23)00267-X
Volume 11, Issue 12, December 2023, Pages 915-925
